PAI Pharma Expands Sterile Injectable Business With Nexus Pharmaceuticals Acquisition
Key Points
- PAI Pharma has acquired Nexus Pharmaceuticals, adding more than 20 hospital injectable products to its portfolio
- The deal strengthens PAI's position in the U.S. sterile injectable market and builds on its Nivagen aseptic manufacturing acquisition in Sacramento
- The combined company broadens oral liquid, ready-to-use injectable and other hospital products for U.S. healthcare providers
PAI Pharma has acquired Nexus Pharmaceuticals, adding more than 20 hospital injectable products to its portfolio and further strengthening its position in the U.S. sterile injectable market. The transaction brings together two companies with complementary pharmaceutical offerings and capabilities. Parsippany, NJ-based PAI develops, manufactures, and markets oral liquid medicines, ready-to-use (RTU) sterile injectables, and other products for hospital use. Nexus, headquartered in Lincolnshire, Illinois, specializes in developing and commercializing injectable therapies for critical care, oncology, and other hospital-based applications.
The acquisition supports PAI’s broader strategy to expand its supply of essential medicines and build a stronger presence in the hospital pharmaceutical sector. Nexus contributes an established portfolio of more than 20 injectable products, along with longstanding relationships throughout the U.S. hospital market and experience bringing critical therapies to commercialization.
The deal also builds on PAI’s recent investments in domestic sterile manufacturing. Its acquisition of Nivagen added aseptic manufacturing capabilities in Sacramento, California, complementing the company’s existing pharmaceutical development and production operations.
With the addition of Nexus, PAI expects to broaden the range of products it can offer hospitals and healthcare providers, combining its expertise in oral liquid and ready-to-use formulations with Nexus’ injectable drug portfolio and commercial infrastructure.
Nexus focuses in part on complex injectable medicines, including products addressing areas where supply constraints have historically affected availability. The company draws on its pharmaceutical development and analytical capabilities, contract manufacturing network, and established customer relationships to support commercialization.
The acquisition represents another step in PAI’s efforts to expand its U.S. manufacturing footprint and strengthen its position as a supplier of pharmaceutical products for hospital and healthcare markets.
Visit www.paipharma.com for more information.
Total Page Views: 2
